Analysts await Pfenex Inc. (NASDAQ:PFNX) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.46 EPS, down 36.96% or $0.17 from last year’s $-0.29 per share.

At the moment 5 analysts are watching Pfenex Inc. (NASDAQ:PFNX), 1 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 4 analysts have a mean sales target of 2.37 million. For the quarter ending Sep-16, 4 analysts have a mean sales target of 2.40 million whilst for the year ending Dec-16, 5 analysts have a mean target of 9.79 million.

In terms of earnings per share, 5 analysts have a -0.48 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 5 analysts have a -0.51 EPS mean target and for the quarter ending Sep-16 there are 5 estimates of -1.97 EPS.

The biggest institutional shareholders in Pfenex Inc. include Franklin Advisers, Inc. which owns 4 million shares in the company valued at $44.10 million. PRIMECAP Management Company is the second biggest holder with 2 million shares currently valued at 30.10 million whilst Dow Chemical Co has 2 million shares valued at 27.50 million.

Total shares held by institutions as of the most recent company filings are 17,484,894 with a reported 956,054 bought and 2,856,806 sold. These holdings make up 74.81% of the company’s outstanding shares.

Currently insiders hold 748,234 shares in the business which makes up 3.20% of shares. The biggest holder currently is Dr. Bertrand C. Liang who owns 522,466 shares (2.24% of those outstanding), whilst Dr. Henry W. Talbot holds 118,678 (0.51% of shares outstanding) and Mr. Patrick K. Lucy holds 105,690 (0.45% of shares outstanding).

The stock decreased 3.23% or $0.27 during the last trading session, hitting $8.07. Pfenex Inc. (NASDAQ:PFNX) has fallen 110.41% over the past 6 months and is downtrending.